0000934549FALSE00009345492024-01-192024-01-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 19, 2024
ACACIA RESEARCH CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
| Delaware |
001-37721 |
95-4405754 |
(State or other jurisdiction of
incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
|
| 767 Third Avenue, |
|
| 6th Floor |
|
| New York, |
|
| NY |
10017
|
| (Address of principal executive offices) |
(Zip Code) |
(Registrant’s telephone number, including area code): (332) 236-8500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
| o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
| o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
| o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
| o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
| Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
ACTG |
The Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
|
|
|
|
|
| Item 2.01. |
|
Completion of Acquisition or Disposition of Assets
|
On January 19, 2024, Acacia Research Corporation (the “Company”) completed the sale of its 33,023,210 shares of Arix Bioscience PLC (“Arix”) to RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP). Following the completion of the share sale, the Company no longer owns any shares of Arix.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Dated: January 22, 2024 |
|
|
ACACIA RESEARCH CORPORATION |
|
|
|
By: |
/s/ Jason Soncini |
|
Name: |
Jason Soncini |
|
Title: |
General Counsel |
エドガーで原本を確認する